Article Figures & Data
Figures
- Fig 1.
A and B, Perfusion maps overlaid on postcontrast T1-weighted image (A) in an enhancing mass lesion of the brain. The large green region of interest placed on the enhancing mass lesion to measure the mean signal-intensity recovery shows overshoot from baseline on the recovery maps (B). The lesion proved to be a lymphoma on histopathology. C and D, Perfusion maps overlaid on postcontrast T1-weighted image (C) in a mass lesion of the brain surrounded by significant edema, which proved to be GBM on histopathology. The large green region of interest placed on the enhancing mass lesion shows approximately 77% mean signal-intensity recovery on the recovery maps (D). E and F, Perfusion maps overlaid on postcontrast T1-weighted image (E) in an enhancing mass lesion of the brain. The large green region of interest placed on the enhancing mass lesion shows about 32% mean signal-intensity recovery on the recovery maps (F). The lesion proved to be a metastases on histopathology.
- Fig 2.
Boxplots showing various perfusion parameters like rCBV (A), mean PSR (B), max PSR (C), and min PSR (D) in differentiating lymphoma, GBM, and metastases.
- Fig 3.
A, ROC for comparison of mean PSR, max PSR, and max rCBV in an enhancing lesion for differentiation of lymphoma from GBM and metastases. B, ROC for comparison of mean PSR, min PSR, and max rCBV in an enhancing lesion in differentiating metastases from GBM and lymphoma. C, ROC for comparison of mean PSR in an enhancing lesion and PSR and max rCBV in the peritumoral region.
Tables
- Table 1:
Mean values and SDs of perfusion parameters in differentiating malignant lesions of the brain
Contrast-Enhancing Lesion Perienhancing Lesion rCBV Mean PSR Ratio Max PSR Ratio Min PSR Ratio rCBV Mean PSR Ratio Lymphoma 2.43 ± 1.19 113.15 ± 41.59 158.86 ± 87.06 89.57 ± 23.63 0.87 ± 0.17 99.80 ± 25.33 GBM 4.72 ± 2.19 78.22 ± 14.27 87.06 ± 13.16 66.04 ± 16.24 1.39 ± 0.51 93.00 ± 10.50 Metastases 2.93 ± 1.18 53.46 ± 12.87 55.76 ± 12.56 41.82 ± 12.95 0.48 ± 0.26 80.97 ± 8 P value lymphoma from GBM .000 .001 .000 .015 .002 .16 P value GBM vs metastases .021 .000 .000 .000 .001 .000 F (ANOVA) >11.1 >29.9 >23.4 >39.3 >18.4 >7.2 Enhancing Lesion Perienhancing Lesion rCBV Mean PSR Max PSR Min PSR rCBV PSR Lymphoma from GBM and metastases .759 (.634–.884) .880 (.789–.970) .933 (.877–.990) .909 (.828–.990) .608 (.461–.756) .658 (.494–.822) Metastases from GBM and lymphoma .534 (.391–.676) .938 (0.884–0.990) .928 (0.824–0.973) .938 (.884–.991) .798 (.662–.929) .849 (.737–.961) Comparison χ2 P Value Differentiation of metastases from GBM and lymphoma Mean PSR vs rCBV 24.1782 <.0001 Minimum PSR vs mean PSR 0.0000 1.0000 Differentiation of lymphoma from GBM and metastases Maximum PSR vs rCBV 6.4777 <.011 Maximum PSR vs mean PSR 3.3210 .0684 -
a Tested for significance using the bivariate χ2 test.
-
Threshold Sensitivity Specificity Max PSR % in lymphoma from other >94 100 69 >114 82 93 >136 72 100 Mean PSR % in lymphoma from other >70 100 34 >120 59 100 >103 78 94 Mean PSR % in metastases from other <40 .50 100 <75 100 83 <67 95 85 Min PSR % in metastases from other <40 .50 100 <72 100 81 <51 86 89
In this issue
Jump to section
Related Articles
Cited By...
- Multisite Benchmark Study for Standardized Relative CBV in Untreated Brain Metastases Using the DSC-MRI Consensus Acquisition Protocol
- "Synthetic" DSC Perfusion MRI with Adjustable Acquisition Parameters in Brain Tumors Using Dynamic Spin-and-Gradient-Echo Echoplanar Imaging
- Deep Learning of Time-Signal Intensity Curves from Dynamic Susceptibility Contrast Imaging Enables Tissue Labeling and Prediction of Survival in Glioblastoma
- Deep Learning of Time-Signal Intensity Curves from Dynamic Susceptibility Contrast Imaging Enables Tissue Labeling and Prediction of Survival in Glioblastoma
- Diffuse Large B-Cell Epstein-Barr Virus-Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics
- Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI
- Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma
- Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object
- Added Value of Spectroscopy to Perfusion MRI in the Differential Diagnostic Performance of Common Malignant Brain Tumors
- Contrast Leakage Patterns from Dynamic Susceptibility Contrast Perfusion MRI in the Grading of Primary Pediatric Brain Tumors
- Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
- Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
- The Effect of Pulse Sequence Parameters and Contrast Agent Dose on Percentage Signal Recovery in DSC-MRI: Implications for Clinical Applications
- Differentiation of Primary Central Nervous System Lymphomas and Glioblastomas: Comparisons of Diagnostic Performance of Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging without and with Contrast-Leakage Correction
- Diagnostic Accuracy of Dynamic Contrast-Enhanced MR Imaging Using a Phase-Derived Vascular Input Function in the Preoperative Grading of Gliomas
- The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard